BeiGene CEO John Oyler discusses the breadth of the company's pipeline at #ASCO24
John Oyler discusses the company's marketed BTK and PD-1 therapies, and highlights a handful of programs and targets in the pipeline like HPK1, ADCs, and protein degraders.